Related Experiment Video
Updated: Sep 4, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Chronic Kidney Disease Is Associated With Increased Cardiac Corin Expression But Decreased Proatrial Natriuretic
Shang-Feng Yang1,2, Szu-Yuan Li3,4, Feng-Yen Lin5,6
1Division of Nephrology, Department of Medicine Cheng Hsin General Hospital Taipei Taiwan.
Insights
Chronic kidney disease (CKD) increases cardiovascular risk. In CKD, corin (a protease) levels rise but its activity decreases, potentially causing cardiomyopathy due to reduced PCSK6 expression.
Area of Science:
- Cardiovascular Research
- Nephrology
- Biochemistry
Background:
- Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease.
- The PCSK6/corin/atrial natriuretic peptide pathway's role in CKD-induced cardiomyopathy is not well understood.
Purpose of the Study:
- To investigate the role of the PCSK6/corin/atrial natriuretic peptide pathway in CKD-associated cardiomyopathy.
- To compare corin levels and activity in patients with and without CKD.
Main Methods:
- Serum corin, left ventricular mass index, and their correlation were analyzed in 543 patients with or without CKD.
- Cardiac corin expression and activity were compared in CKD animal models and controls.
- In vitro studies examined the effects of indoxyl sulfate on cardiomyocytes.
Main Results:
- Patients with CKD exhibited elevated serum corin levels.
- Serum corin correlated negatively with left ventricular mass index in non-CKD participants but not in CKD patients.
- CKD mice showed increased serum and cardiac corin but reduced cardiac corin activity, linked to lower PCSK6 expression.
Conclusions:
- CKD is associated with increased cardiac and serum corin levels but suppressed corin activity.
- Reduced PCSK6 expression may underlie the diminished corin activity in CKD.
- Corin dysfunction is implicated in the pathogenesis of CKD-associated cardiomyopathy.
Abstract:
Background Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular disease. Corin converts proatrial natriuretic peptide into its active form after being activated by PCSK6 (proprotein convertase subtilisin/kexin type 6) protease. It remains unknown whether the PCSK6/corin/atrial natriuretic peptide pathway plays a role in CKD-induced cardiomyopathy. Methods and Results Serum corin, left ventricular mass index, and corin-left ventricular mass index correlation were compared between outpatients with versus without CKD. Cardiac corin expression and activity as well as serum corin were compared between 5/6 nephrectomy CKD animal models and sham controls. The effects of indoxyl sulfate, a uremic toxin, on cardiomyocytes were examined in vitro in H9c2 cells. A total of 543 patients were enrolled in this study. Serum corin levels were elevated in patients with CKD compared with levels in patients without CKD. Serum corin levels correlated negatively with left ventricular mass index in participants without CKD, but not in patients with CKD. Compared with sham controls, CKD mice had higher serum corin levels and increased cardiac expression of corin but reduced cardiac corin conversion activity. Indoxyl sulfate stimulated corin expression while suppressing serine protease activity in H9c2 cardiomyoblasts. Lower PCSK6 expression in CKD mouse hearts and indoxyl sulfate-treated H9c2 cardiomyoblasts may explain, at least partly, the observed CKD-associated reduction in corin activity. Conclusions In CKD, cardiac and serum levels of corin are increased, yet corin activity is suppressed. The latter may be attributable to reduced PCSK6 expression. These findings suggest that corin dysfunction may play a significant role in the pathogenesis of CKD-associated cardiomyopathy.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease I: Introduction
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Chronic Kidney Disease IV: Nursing Management

